Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc
Tumor suppressor gene p53 is the most frequently …
Oncology Data Advisor · i3 Health
January 28, 20225m 35s
Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Tumor suppressor gene p53 is the most frequently mutated gene in human malignancy. Through a complex series of molecular events, p53 leads to malignant cell proliferation and plays a significant role in tumor formation. In this interview with Oncology Data Advisor, Dr. Matthew Davids of Harvard Medical School delves further into the latest research in p53-directed therapeutic strategies and the future of targeting this specific mutation.